BioWorld

Feb. 15, 2010

View Archived Issues

Safety Brouhaha Tests 'Mettle' of Feraheme After Downgrade

Alexza Just See: Biovail Deal Spotlights AZ-004's Way Forth

Money Raised By Biotech in 2010

Week in Review

Word on the Street

Week in Washington

FDA Approvals In January

Phase I Clinical Trials Update: January 2010

Phase II Clinical Trials Update: January 2010

Pivotal/Phase III Clinical Trials Update: February 2010

Non-U.S. Clinical Trials And Regulatory Actions: February 2010

Celera's Hidden Treasure: A 'Royal' Road to Payoff?

Last week, the Biotechnology Value Fund (BVF) proposed that Celera Corp. separate its low margin diagnostics business from its potentially high-margin drug royalty stream. Read More

Money Raised Year to Date

FDA Submissions, Approvals And Other Actions: February 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

In the clinic for June 12, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...